TED

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

Retrieved on: 
Wednesday, January 10, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Amgen, TED, Teprotumumab, Graves' ophthalmopathy, License, Pharmaceutical industry

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease.

Key Points: 
  • Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease.
  • Teprotumumab-trbw is known as TEPEZZA® in the United States.
  • “We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneous teprotumumab to potentially enhance the patient experience and delivery of the treatment for Thyroid Eye Disease.
  • This agreement to license XeriJect further validates the potential value of our technology to enable large molecule subcutaneous injections that provide a more patient friendly regimen that is effective, safe, and more convenient, with potential for improved adherence,” said Paul R. Edick, Chairman and CEO of Xeris.

Webflow names Rachel Wolan as Chief Product Officer

Retrieved on: 
Wednesday, January 10, 2024
SAN, Command, IDEO, App, The New York Times, LiveRamp, Acquisition, Publishing, CPO, TED, Engineering, News

Wolan is a seasoned product executive who has led product, engineering, data, and design teams across both startups and mature public companies including LiveRamp, Euclid Analytics, and Talkdesk.

Key Points: 
  • Wolan is a seasoned product executive who has led product, engineering, data, and design teams across both startups and mature public companies including LiveRamp, Euclid Analytics, and Talkdesk.
  • Webflow has continued to expand its product offerings this year, introducing new capabilities to support collaboration for enterprise teams of marketers, content writers, and developers.
  • "Rachel's exceptional background and unparalleled expertise in product, sales, and web development make her the perfect addition to our team as Webflow enters this next growth phase," said Vlad Magdalin, CEO of Webflow.
  • Late last year, Webflow promoted Chief Operating Officer Linda Tong to President and welcomed Allan Leinwand as Chief Technology Officer.

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Continuity, Diabetes, Entrepreneurship, Risk, C3, Non-alcoholic fatty liver disease, Epilepsy, FDA, CR2, Anticonvulsant, Inflammation, Neuron, Geographic atrophy, Conference, Paratriathlon, Pain, European, Disease, Cmax, Glycated hemoglobin, Trigeminal neuralgia, FGF21, Steatosis, Therapy, Computational biology, Exophthalmos, TED, Diplopia, Varenicline, Smoking, Injection, AAV, CNS, DSM-IV codes, Patient, Graves' ophthalmopathy, Medicine, Seizure, Glucokinase, Neurology, CR1, NASH, Insulin, Brain, GMP, Trigeminal nerve, Ophthalmology, Pathology, Fibrosis, Pharmaceutical industry

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, LDL, TED, Conference, IND, Autoimmunity, Half-life, Graves' ophthalmopathy, Trial of the century, Therapy, New Drug Application, Conditional sentence, Neonatal Fc receptor, Patient, Compensated emancipation, Safety, Employment, Immunoglobulin G, Pharmaceutical industry

As part of Viridian’s presentation at the J.P. Morgan Healthcare Conference, Mr. Mahoney will provide key updates on the company’s anti-insulin-like growth factor 1 receptor (IGF-1R) programs in thyroid eye disease (TED) and its programs targeting FcRn.

Key Points: 
  • As part of Viridian’s presentation at the J.P. Morgan Healthcare Conference, Mr. Mahoney will provide key updates on the company’s anti-insulin-like growth factor 1 receptor (IGF-1R) programs in thyroid eye disease (TED) and its programs targeting FcRn.
  • Viridian is currently evaluating VRDN-001 in two global Phase 3 clinical trials, THRIVE and THRIVE-2, for the treatment of active and chronic TED, respectively.
  • The company expects to report THRIVE and THRIVE-2 data in the middle of 2024 and by year end 2024, respectively.
  • The Inducement Grant was granted as an inducement material to this individual entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).

Xperi Expands its Global Footprint with its Powered by TiVo Media Platform for Smart TVs and Connected Car

Retrieved on: 
Monday, January 8, 2024
Consumer Electronics, Automotive, Technology, Online, Mobile Entertainment, Entertainment, Other Technology, General Automotive, Internet, Hardware, Other Entertainment, Annual report, TED, BMW, Partnership, Konka, CTV Life Channel, DTS, OEM, Tubi, Electronics, DW, News, Original equipment manufacturer, Pluto TV, DAZN, PLEX, NTV, NEWS, Yahoo!, Television, Human, Nippon TV, Sport, Machine learning, Park MGM, Content, Growth, CES, OS, ZDF, Bloomberg, CTV, TiVo, History, Power, WOWOW

Over the past 12 months, Xperi has experienced rapid success with its independent media platforms.

Key Points: 
  • Over the past 12 months, Xperi has experienced rapid success with its independent media platforms.
  • TiVo OS for smart TVs and DTS AutoStage Video Service Powered by TiVo for connected cars are focused on delivering an extraordinary entertainment experience in a way that feels more intuitive, immersive and personal.
  • In the latter half of 2023, Vestel, TiVo’s first OEM partner, began to release smart TVs to market.
  • Beginning in Spring 2024, leading UK retailer Argos is expected to offer Powered by TiVo TVs through their Bush TV brand.

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

Retrieved on: 
Monday, January 8, 2024
TED, Quality of life, Entrepreneurship, TRML, C-reactive protein, Diplopia, Membrane protein, Moyamoya disease, FDA, Alignment, Inflammation, Injection, Spirited, Half-life, MD, Pharmacokinetics, IL-6, Biomarker, Patient, Safety, Cardiovascular disease, CRP, CAS, Exophthalmos, Pharmaceutical industry

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that:

Key Points: 
  • This second pivotal trial will replace the previously planned TED basket trial and does not impact Tourmaline’s expected cash runway through 2026.
  • This trial is targeted to commence in the first half of 2024, with topline data expected in the first half of 2025.
  • Pending success, the results from the Phase 2 trial are expected to position Tourmaline to be ready in 2025 to commence a pivotal Phase 3 trial in cardiovascular disease.
  • To date, TOUR006 has been studied in 448 participants, including patients with autoimmune disorders, across six clinical trials.

Kriya Announces Gene Therapy Program for Thyroid Eye Disease

Retrieved on: 
Friday, January 5, 2024
TED, Quality of life, Entrepreneurship, Conference, Geographic atrophy, Diplopia, Teprotumumab, Fibroblast, FDA, Paratriathlon, European, Disease, Graves' ophthalmopathy, Eye, Therapy, Inflammation, Adipocyte, PALO, AAV, Ophthalmology, Cell, Exophthalmos

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., (Kriya) a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today announced its gene therapy program for thyroid eye disease (TED), a debilitating autoimmune condition resulting in proptosis and diplopia, medical terms describing bulging of the eyes and double vision respectively, due to inflammation of the muscles and fat tissue behind the eye. TED affects approximately one million people in the United States and the European Union.

Key Points: 
  • TED affects approximately one million people in the United States and the European Union.
  • Kriya is developing KRIYA-586, a one-time, adeno-associated virus (AAV) gene therapy that drives durable expression of a monoclonal antibody that blocks IGF-1 receptors.
  • IGF-1R blockade has been established as a clinically validated mechanism of action, as evidenced by teprotumumab, the first and only FDA-approved therapy for TED.
  • "We believe that an in-office, focally administered gene therapy for TED would meaningfully improve the quality of life of people with TED, with the potential to durably address the disease following one-time injection,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya.

PropertyGuru Asia Real Estate Summit concludes ninth edition, focusing on 'Powering Communities'

Retrieved on: 
Monday, December 18, 2023
Yee, Central Waqf Council, Real estate, Property Report, World Green Building Council, Property, Disability, Fintech, Communication, Travel, Parsons School of Design, Work, HLB International, Creative director, Business, A.I, GM, University, E-commerce, Consultant, ARES, TED, CBRE, Quantum, Digital, Manila Bulletin, Language, Community, Sunlight, Rem, COP28, City, Next, Michelin Guide, Leisure, City Developments Limited, Investment, Architect, Management

Hari Krishnan, PropertyGuru Group, Chief Executive Officer & Managing Director, delivering the Opening Keynote

Key Points: 
  • Hari Krishnan, PropertyGuru Group, Chief Executive Officer & Managing Director, delivering the Opening Keynote
    ARES Visionary of the Year awardee Ar.
  • This year's theme aligns with PropertyGuru Group's vision to power communities to live, work, and thrive in tomorrow's cities.
  • The first panel discussion of the day was led by Manav Kamboj, Chief Technology Officer and Managing Director, Fintech at PropertyGuru Group.
  • PropertyGuru Asia Real Estate Summit 2023 is supported by official portal partner PropertyGuru; official magazine Property Report by PropertyGuru; official publicity partner Artemis Associates; media partners Bridges, d+a Magazine, Hot Magazine, Manila Bulletin, Powderlife, REm, and Techsauce; and supporting associations IFC ?

Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease

Retrieved on: 
Tuesday, December 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, TED, IND, Alta Partners, FDA, IPF, Cell proliferation, Therapy, MHRA, Cancer, Pharmacokinetics, Medicine, Series, Collagen, Patient, CTA, Pharmaceutical industry

The syndicate also included new investors BVF Partners and Catalio Capital Management as well as existing investors, Alta Partners and Longwood Capital.

Key Points: 
  • The syndicate also included new investors BVF Partners and Catalio Capital Management as well as existing investors, Alta Partners and Longwood Capital.
  • Proceeds from this financing will support the LASN01 clinical program and advance IND-enabling activities for LASN500.
  • The clinical program for LASN01 is focused primarily in TED with a cohort in IPF in the Phase 1 program.
  • “The proceeds allow us to advance LASN01 Phase 1 and 2 clinical programs and develop a subcutaneous formulation for LASN01.

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Well, Pivotal, Therapy, TED, Graves' ophthalmopathy, PD, ADAS, Serum, Data, Patient, Clinical study design, Cavg, Cmin, Pharmacology, Half-life, Trial of the century, Stiffness, Growth, Pharmaceutical industry, Vaccine, Copper, Viridian

“The data reinforce our confidence in VRDN-003’s rapid development as a low-volume, self-administered, subcutaneous product.

Key Points: 
  • “The data reinforce our confidence in VRDN-003’s rapid development as a low-volume, self-administered, subcutaneous product.
  • VRDN-003 is designed to maintain the clinical response of VRDN-001 IV while significantly increasing patient convenience.
  • Dosing Flexibility for Pivotal Development: VRDN-003 modeling demonstrates dosing flexibility for the program’s anticipated global pivotal development.
  • Based on these positive results and the expected development timeline for VRDN-003, both VRDN-001 SC and VRDN-002 SC development have been deprioritized.